Overall, investigation of epigenetic drugs for Ewing sarcoma treatment is still in its infancy but there is clear evidence that these agents can disrupt EWS::FLI1 transcriptional activity and inhibit fusion-driven gene signatures. Here, EWSR1 is linked to Ewing sarcoma.